Small molecule · Inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1) and mitogen-activated protein kinase kinase 2 (MAP2K2) · developed by Astrazeneca
Selumetinib is a small-molecule kinase inhibitor of MEK1 and MEK2, upstream regulators of the ERK pathway in the RAS-RAF-MEK-ERK cascade. It is studied in non-small cell lung cancer, and it is used in neurofibromatosis type 1 with plexiform neurofibromas.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of May 26, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04924608 | Phase 3 | Neurofibromatosis 1 | Active not recruiting | AZN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Updated Nov 15, 2026. Something wrong or missing? Report it on the AZN page.
See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AZN catalysts and pipeline →